J
Jerome Guillemont
Researcher at Janssen-Cilag
Publications - 29
Citations - 4768
Jerome Guillemont is an academic researcher from Janssen-Cilag. The author has contributed to research in topics: Mycobacterium tuberculosis & ATP synthase. The author has an hindex of 13, co-authored 27 publications receiving 4309 citations. Previous affiliations of Jerome Guillemont include Johnson & Johnson Pharmaceutical Research and Development & Johnson & Johnson.
Papers
More filters
Journal ArticleDOI
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Koen Andries,Peter Verhasselt,Jerome Guillemont,Hinrich W. H. Göhlmann,Jean-Marc Neefs,Hans Winkler,Jef Van Gestel,Philip Timmerman,Min Zhu,Ennis Lee,Peter Williams,Didier de Chaffoy,Emma Huitric,Sven Hoffner,Emmanuelle Cambau,Chantal Truffot-Pernot,Nacer Lounis,Vincent Jarlier +17 more
TL;DR: A diarylquinoline, R207910, is identified that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.
Journal ArticleDOI
The challenge of new drug discovery for tuberculosis
TL;DR: In this review, innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients are discussed.
Journal ArticleDOI
Diarylquinolines target subunit c of mycobacterial ATP synthase.
Anil Koul,Najoua Dendouga,Karen Vergauwen,Brenda Molenberghs,Luc Vranckx,Rudy Edmond Willebrords,Zorica Ristic,Holger Lill,Ismet Dorange,Jerome Guillemont,Dirk Bald,Koen Andries +11 more
TL;DR: It is established by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910, and targeting energy metabolism is a new, promising approach for antibacterial drug discovery.
Journal ArticleDOI
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Paul A. J. Janssen,Paul J. Lewi,Eddy Arnold,Frits Daeyaert,Marc René De Jonge,Jan Heeres,Luc Koymans,Maarten Vinkers,Jerome Guillemont,Elisabeth Thérèse Jeanne Pasquier,Mike Kukla,Don Ludovici,Koen Andries,Marie-Pierre de Béthune,Rudi Pauwels,Kalyan Das,A.D. Clark Jr,Yulia Volovik Frenkel,Stephen H. Hughes,Bart Petrus Anna Maria Jozef Medaer,Fons De Knaep,Hilde Bohets,Fred De Clerck,Ann Lampo,Peter D. Williams,Paul Stoffels +25 more
TL;DR: R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet criteria and to be suitable for high compliance oral treatment of HIV-1 infection.
Journal ArticleDOI
Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Anil Koul,Luc Vranckx,Najoua Dendouga,W Balemans,Ilse Van den Wyngaert,Karen Vergauwen,Hinrich W. H. Göhlmann,Rudy Edmond Willebrords,Alain Philippe Poncelet,Jerome Guillemont,Dirk Bald,Koen Andries +11 more
TL;DR: It is concluded that this residual ATP synthase activity is indispensable for the survival of dormant mycobacteria, making it a promising drug target to tackle dormant infections.